SALT
LAKE CITY, Sept. 22, 2023 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or
"Co-Dx"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests,
announced today that Co-Diagnostics will be hosting a booth and
presenting at the 6th Advances in Circulating Tumor
Cells ("ACTC") conference held this week in Skiathos, Greece.
This year's meeting will focus on the latest advances and
clinical applications of liquid biopsy, with presentations on CTCs,
circulating tumor DNA, circulating miRNAs and more. The Company's
participation will include a poster sharing research into potential
use of its Co-Primers™ technology in liquid biopsy applications, as
well as a brief presentation about the upcoming Co-Dx PCR
Home™ platform and its potential to transform infectious
disease diagnosis worldwide.
More information about the conference can be found here. Parties
interested in learning more about the Company's products or
research into liquid biopsy are invited to visit Booth #9.
The Co-Dx PCR Home platform is subject to FDA review and is
not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR Home™ platform and to locate
genetic markers for use in applications other than infectious
disease.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-in-6th-actc-conference-in-skiathos-greece-301935708.html
SOURCE Co-Diagnostics